SPPiRE Prescriptions and Potentially Inappropriate Prescribing (PIP) Criteria Study Notes

Overview of SPPiRE Prescriptions and Potentially Inappropriate Prescribing (PIP) Criteria

  • Source and Basis: The criteria are based on a range of international explicit indicators designed for safer prescribing, specifically utilizing the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) indicators.

  • Definition of PIP: Potential Inappropriate Prescribing occurs when medications are prescribed in a way that risks outweigh the clinical benefits, or when specific clinical guidelines regarding duration and safety monitoring are not followed.

  • Focus Areas: The criteria primarily target drug groups frequently associated with preventable drug-related morbidity and drug groups associated with morbidity in the elderly population.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 Selective Inhibitors

  • NSAIDs combined with Diuretics and ACEi/ARB:

    • Criterion: Prescribing an NSAID simultaneously with a diuretic and an Angiotensin-Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB).

    • Reason: This combination significantly increases the risk of renal impairment.

  • NSAIDs in Chronic Kidney Disease:

    • Criterion: Use in patients with chronic kidney disease where the estimated glomerular filtration rate (eGFReGFR) is <50 ml/min/1.73m2< 50\,ml/min/1.73m^2.

    • Reason: High risk of further renal impairment.

  • NSAID Duration and Gastroprotection:

    • Criterion 1: Regular use for a duration of ≥12\ge 12 weeks without accompanying gastroprotection.

    • Criterion 2: Non-COX-2 selective NSAIDs used in patients with a history of Peptic Ulcer Disease (PUD) without gastroprotection.

    • Criterion 3: NSAIDs used in combination with antiplatelet therapy without gastroprotection.

    • Reason: These scenarios carry a high risk of Gastro-Intestinal (GI) bleeding.

  • NSAIDs with Anticoagulants:

    • Criterion: Concurrent use of an NSAID and an anticoagulant.

    • Reason: Significant risk of GI bleeding.

  • NSAIDs in Cardiovascular and Respiratory Conditions:

    • Criterion: Use in patients with severe hypertension or heart failure.

    • Reason: Risk of exacerbating hypertension or heart failure symptoms.

  • COX-2 Selective Inhibitors:

    • Criterion: Use of COX-2 selective inhibitors in patients with concurrent cardiovascular disease.

    • Reason: Associated with an increased risk of Myocardial Infarction (MI) or Cerebrovascular Accident (CVA).

Antiplatelet and Anticoagulant Therapy

  • Antiplatelet Risks:

    • PUD History: Use in patients with a history of Peptic Ulcer Disease (PUD) without gastroprotection increases the risk of GI bleeding.

    • Anticoagulant Co-prescription: Use with an anticoagulant without gastroprotection increases the risk of GI bleeding.

    • Dual Antiplatelet Therapy (DAPT): Use of DAPT without gastroprotection increases GI bleed risk.

    • PCI Follow-up: The intended duration of treatment for dual antiplatelet therapy should be carefully considered if it exceeds one year post-Percutaneous Coronary Intervention (PCI), as it is usually not indicated beyond this point.

  • Anticoagulant Duration and Indications:

    • First Uncomplicated DVT: Anticoagulant use for a duration of >6> 6 months for a first uncomplicated Deep Vein Thrombosis (DVT) is not indicated.

    • First Uncomplicated PE: Anticoagulant use for a duration of >12> 12 months for a first uncomplicated Pulmonary Embolism (PE) is not indicated.

  • Direct Oral Anticoagulants (DOACs) and Renal Function:

    • Dabigatran (Pradaxa): PIP occurs if prescribed when eGFR<30 ml/min/1.73m2eGFR < 30\,ml/min/1.73m^2 or if renal function is unknown, due to the risk of bleeding.

    • Rivaroxaban (Xarelto) and Apixaban (Eliquis): PIP occurs if prescribed when eGFR<15 ml/min/1.73m2eGFR < 15\,ml/min/1.73m^2 or if renal function is unknown, due to the risk of bleeding.

Diuretic Therapy and Monitoring

  • Safety Monitoring (U&Es):

    • General Diuretic Monitoring: Prescribing a diuretic with no Urea and Electrolyte (U&E) check in the last 4848 weeks is considered PIP due to the risk of renal impairment and electrolyte abnormality.

    • Combination Diuretics: Use of a loop diuretic and a thiazide diuretic together with no U&E check in the last 2424 weeks carries similar risks of renal and electrolyte issues.

  • Appropriateness of Indication:

    • Loop Diuretics for Dependent Oedema: Prescribing a loop diuretic solely for dependent oedema in the absence of heart failure, liver failure, or nephrotic syndrome is inappropriate; the risks usually outweigh the benefits.

    • Thiazide Diuretics and Gout: Use of thiazide diuretics in patients with a history of gout is inappropriate due to the risk of precipitating a gout flare.

Medications Associated with Morbidity in the Elderly

  • Anticholinergic Drugs and Comorbidities:

    • High-Risk Conditions: Anticholinergic drugs should be avoided or used with extreme caution in patients with Dementia, Narrow-angle glaucoma, Cardiac conduction abnormalities, or Chronic prostatism, as they can exacerbate these co-morbidities.

    • Anticholinergic Toxicity: Concomitant use of two or more drugs with anticholinergic properties increases the risk of anticholinergic toxicity.

  • Specific Antidepressants and Antihistamines:

    • Tricyclic Antidepressants (TCAs): Should not be used as first-line antidepressants in older patients due to an increased risk of adverse effects and the availability of safer alternatives.

    • Antimuscarinic Antihistamines: Use is associated with increased morbidity risk in the elderly.

  • Sedative-Hypnotics (Benzodiazepines and Z-drugs):

    • Duration: Use for longer than 44 weeks is inappropriate.

    • Risks: High risk of sedation, confusion, impaired balance, and falls.

    • Statistical Impact for Insomnia: The Number Needed to Treat (NNTNNT) is 1313, while the Number Needed to Harm (NNHNNH) is only 66.

  • Antipsychotics in Patients with Dementia:

    • Indication Constraint: Use in patients with dementia who do not have psychosis is inappropriate.

    • Risks: Associated with an increased risk of stroke.

    • Usage Guidelines: Should only be used when all other means have failed, at the shortest possible dose for the shortest possible duration.

Miscellaneous Drug Groups and High-Risk Scenarios

  • Methotrexate Safety:

    • Frequency: To avoid potentially fatal medication errors, it must be prescribed as a weekly dose.

    • Strength: Prescribing more than one strength of tablet is considered a high risk for error.

  • Opioid Management:

    • Laxative Co-prescription: Regular use of opioids without a laxative is inappropriate due to the high risk of severe constipation.

  • Corticosteroid Use:

    • Bone Protection: Use for ≥12\ge 12 weeks without bone protection is inappropriate due to the significantly increased risk of fracture.

  • Proton Pump Inhibitors (PPIs):

    • Duration: Full therapeutic dose for ≥8\ge 8 weeks in cases of uncomplicated PUD or erosive peptic oesophagitis is not indicated.

  • Metformin in Renal Impairment:

    • Threshold: Prescription when eGFR<30 ml/min/1.73m2eGFR < 30\,ml/min/1.73m^2 is inappropriate due to the risk of lactic acidosis.

Abbreviations and Technical Definitions

  • ACEi: Angiotensin converting enzyme inhibitor

  • ARB: Aldosterone receptor blocker (also known as Angiotensin II receptor blocker)

  • COX-2: Cyclooxygenase-2

  • CVA: Cerebrovascular accident

  • DVT: Deep vein thrombosis

  • eGFR: Estimated glomerular filtration rate

  • GI: Gastro-intestinal

  • MI: Myocardial infarction

  • NNH: Number needed to harm

  • NNT: Number needed to treat

  • NSAID: Non-steroidal anti-inflammatory drug

  • PCI: Percutaneous coronary intervention

  • PE: Pulmonary embolism

  • PUD: Peptic ulcer disease

  • U&E: Urea and Electrolytes

Referenced Literature

  1. Dreischulte T, et al. (2012): Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria. BMC clinical pharmacology; 12:5.

  2. O'Mahony D, et al. (2015): STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and ageing; 44(2):213-8.

  3. Clyne B, et al. (2013): Addressing potentially inappropriate prescribing in older patients: development and pilot study of an intervention in primary care (the OPTI-SCRIPT study). BMC health services research; 13:307.

  4. Glass J, et al. (2005): Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Bmj; 331(7526):1169.

  5. Ballard CG, et al. (2006): Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews; (1).